Biotechnology And Medicare’s New Technology Policy: Lessons From Three Case Studies-Reference-Cited by-同舟云学术

Biotechnology And Medicare’s New Technology Policy: Lessons From Three Case Studies

Published:2006-09 Issue:5 Volume:25 Page:1260-1269
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Keenan Patricia Seliger,Neumann Peter J.,Phillips Kathryn A.¹

Affiliation:

1. Division of Health Policy and Administration, Department of Epidemiology and Public Health, at the Yale University School of Medicine in New Haven, Connecticut.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference13 articles.

1. Medicare Coverage of ICDs

2. Medicare Coverage of ICDs

3. Medicare Coverage of ICDs

4. S.R. Tunis and J.L. Kang, “Improvements in Medicare Coverage of New Technology,”Health Affairs20, no. 5 ( 2001 ): 83 –85

5. ; S.B. Foote , “Why Medicare Cannot Promulgate a National Coverage Rule: A Case of Regula Mortis,”Journal of Health Politics, Policy and Law27, no. 5 ( 2002 ): 708 –730

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiation oncologists’ attitudes and beliefs about intensity-modulated radiation therapy and stereotactic body radiation therapy for prostate cancer;BMC Health Services Research;2020-08-26

2. Medicare and Amyloid PET Imaging: The Battle Over Evidence;Journal of Aging & Social Policy;2016-06-10

3. The Politics of Comparative Effectiveness Research: Lessons from Recent History;Journal of Health Politics, Policy and Law;2013-11-05

4. Illustrating Potential Efficiency Gains from Using Cost-Effectiveness Evidence to Reallocate Medicare Expenditures;Value in Health;2013-06

5. Growth Of High-Cost Intensity-Modulated Radiotherapy For Prostate Cancer Raises Concerns About Overuse;Health Affairs;2012-04